Table 2.

Clinical course during and after low-dose IL-2 therapy.

Case no.	Pt sex	Age	cGVHD dx to study entry (Wks)	No. prior lines tx	Sites involved and cGVHD severity at study entry	LD IL-2 course (Wks)	Response at Week 8 or Week 12	Best overall response	Reason for d/c IL-2	IL-2 stop to last f/u (Wks)	cGVHD status at last f/u	Systemic IS at last f/u
1	M	48	161	1	Skin, JMF; severe	74	PR	PR	Plateaued response	599	Improving subcutaneous fibrosis	None
2	M	65	72	3	Skin, JMF; moderate	132	PR	PR	Plateaued response, difficulty finding injection sites	191	Stable thickened skin	sirolimus, LD prednisone
3	F	22	70	3	Skin, eyes, JMF; severe	86	PR	PR	Plateaued response	204	No active disease; hyperpigmented skin	None
4	F	46	13	2	Mouth, eyes, liver, GU; moderate	258	PR	CR (liver); PR (eyes and mouth)	Stabilized disease, mild fatigue and difficulty picking up IL-2 supply	234	Mild oral and ocular GVHD	None
5	M	29	27	1	Skin, lung, liver, GI, JMF; moderate	244	PR	PR	Plateaued response	244	No active disease	None
6	F	50	71	2	Skin, mouth, JMF; severe	138	PR	PR	Stabilized disease, difficulty picking up IL-2 supply	190	Stable minimal skin cGVHD	None
7	M	61	17	2	Skin, eyes, JMF; moderate	24	SD/MR	SD/MR	Difficulty with daily injections	442	Minimal cGVHD of the eyes, well-controlled	None
8	F	22	50	2	Skin, mouth, eyes, lung, liver, GU; moderate	102	PR	PR	Patient decision	227*	Stable respiratory status on trach/vent#, active skin cGVHD	Tacrolimus, prednisone
9	M	68	226	1	Mouth, eyes, lung; moderate	57	SD/MR	SD/MR	Plateaued response	383	No active disease	None
10	F	70	32	2	Skin, mouth, eyes, lung, liver, JMF; moderate	94	SD/MR	SD/MR	Plateaued response, side effects (anorexia and fatigue)	343	Continued sclerodermatous skin	Ruxolitinib, LD prednisone
11	F	45	10	1	Skin, mouth, eyes, liver, GU; moderate	21	PR	PR	Plateaued response	432	Persistent dry eyes, dry mouth; mild skin involvement	Ruxolitinib
12	F	34	34	2	Skin, eyes, lung, JMF; moderate	80	SD/MR	SD/MR	Stabilized disease, difficulty picking up IL-2 supply	92	No active disease	None
13	M	48	116	2	Skin, mouth, eyes, JMF; moderate	84	SD/MR	SD/MR	Plateaued response	141	Persistent mild skin and JMF involvement	None
14	M	44	241	7	Skin, JMF; severe	104	SD/MR	SD/MR	Plateaued response	206	Persistent severe cGVHD of skin and JMF	Sirolimus, ibrutinib
15	F	59	29	2	Skin, JMF; severe	106	PR	CR	Resolved cGVHD	148	No residual disease	None
16	M	57	26	3	Skin, mouth, liver; moderate	83	PR	PR	Patient decision	201	Residual scleroderma	None
17	F	59	30	3	Skin, eyes, lung, JMF; moderate	177	SD/MR	PR	Plateaued response, side effects	119	Some residual tightness of skin	None
18	F	76	128	3	Skin, eyes, JMF; severe	121	SD/MR	SD/MR	Plateaued response; CLL relapse	196	Residual scleroderma	Ibrutinib
19	F	65	41	2	Skin, lung, JMF; moderate	57	SD	PR	Plateaued response	238	No active disease	None
20	F	21	121	2	Mouth, eyes, GI; moderate	123	Mixed	PR	Plateaued response	137	Persistent eye involvement	None
21	M	12	41	2	Skin, mouth, lung; moderate	141	PR	CR	Plateaued response	100	No active disease; hyperpigmented skin	None
22	M	2	16	2	Skin, mouth, liver, JMF; moderate	139	PR	PR	Plateaued response	101	No active disease; residual hyperpigmented skin and joint contractures	None

*Patient died of multisystem organ failure after a prolonged hospitalization for appendicitis.

^# Patient had progression of lung cGVHD after an infection and underwent tracheostomy with ventilator dependence.

cGVHD, chronic graft-versus-host disease; CLL, chronic lymphocytic leukemia; CR, complete response; Dx, diagnosis; D/c, discontinue; F/u, follow up; GI, gastrointestinal tract; GU, genitourinary tract; IS, immunosuppression; JMF, joint/muscle/fascia; LD, low dose; No., number; PR, partial response; Pt, patient; SD/MR, stable disease with minor response; Trach, tracheostomy; Tx, treatment; Vent, ventilator; Wks, weeks.